Telix Pharmaceuticals Beta vs. Book Value Per Share

TLX Stock   15.42  0.07  0.46%   
Based on Telix Pharmaceuticals' profitability indicators, Telix Pharmaceuticals Limited is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in December. Profitability indicators assess Telix Pharmaceuticals' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 0.41 in 2024. Days Sales Outstanding is likely to drop to 45.23 in 2024. At this time, Telix Pharmaceuticals' Interest Income is fairly stable compared to the past year. Operating Income is likely to rise to about 17.9 M in 2024, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (32 M).
For Telix Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telix Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telix Pharmaceuticals Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telix Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telix Pharmaceuticals Limited over time as well as its relative position and ranking within its peers.
  

Telix Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out World Market Map.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telix Pharmaceuticals. If investors know Telix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telix Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.1
Revenue Per Share
1.991
Quarterly Revenue Growth
0.581
Return On Assets
0.0797
Return On Equity
0.2049
The market value of Telix Pharmaceuticals is measured differently than its book value, which is the value of Telix that is recorded on the company's balance sheet. Investors also form their own opinion of Telix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Telix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Telix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Telix Pharmaceuticals Book Value Per Share vs. Beta Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Telix Pharmaceuticals Limited is currently regarded as top stock in beta category among its peers. It also is currently regarded as top stock in book value per share category among its peers creating about  0.51  of Book Value Per Share per Beta. The ratio of Beta to Book Value Per Share for Telix Pharmaceuticals Limited is roughly  1.97 . At this time, Telix Pharmaceuticals' Book Value Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Telix Book Value Per Share vs. Beta

Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Telix Pharmaceuticals

Beta

 = 

Covariance

Variance

 = 
2.38
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Telix Pharmaceuticals

Book Value per Share

 = 

Common Equity

Average Shares

 = 
1.21 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Telix Book Value Per Share Comparison

Telix Pharmaceuticals is currently under evaluation in book value per share category among its peers.

Beta Analysis

As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Telix Pharmaceuticals will likely underperform.

Telix Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Telix Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telix Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Telix Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Telix Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-33.7 M-32 M
Net Interest Income-12.8 M-12.1 M
Interest IncomeM1.1 M
Operating Income17 M17.9 M
Net Income From Continuing Ops5.2 M5.5 M
Income Before Tax3.1 M3.2 M
Total Other Income Expense Net-13.9 M-13.2 M
Net Income5.2 M5.5 M
Income Tax Expense-2.1 M-2 M
Net Loss(0.14)(0.15)
Income Quality 2.78  2.92 
Net Income Per E B T 1.69  1.25 

Telix Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Telix Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telix Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telix Pharmaceuticals' important profitability drivers and their relationship over time.

Use Telix Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Telix Pharmaceuticals Pair Trading

Telix Pharmaceuticals Limited Pair Trading Analysis

The ability to find closely correlated positions to Telix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telix Pharmaceuticals Limited to buy it.
The correlation of Telix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Telix Pharmaceuticals position

In addition to having Telix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Synthetics Thematic Idea Now

Synthetics
Synthetics Theme
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.